UNSPSC 51313109: Buclizine dihydrochloride

This classification denotes a histamine-1 receptor antagonist with the molecular formula C28H33ClN2.2ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 58FQD093NU, chemically known as piperazine, 1-((4-chlorophenyl)phenylmethyl)-4-((4-(1,1-dimethylethyl)phenyl)methyl)-, dihydrochloride, but more generally known as buclizine dihydrochloride, which bears US NIH Compound Identifier 6729.

European Medicines Agency schedules buclizine dihydrochloride or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05947MIG. Most nations, for tariff purposes, schedule buclizine dihydrochloride under HS 29335995. SMILES: CC(C)(C)C1CCC(CC1)CN2CCN(CC2)C(C3CCCCC3)C4CCC(CC4)CL.CL.CL.

UNSPSC 51313109 Buclizine dihydrochloride is a Commodity code that in practice encompasses a broader range of pharmaceutical procurement by state and local health agencies than its specific name suggests. Recent state and local solicitations tagged to this code reflect active demand for generic pharmaceuticals and over-the-counter health products, including naloxone, drug deactivation systems, and multistate cooperative purchasing agreements for generic medication inventories. Issuing bodies include county health departments, state health and human services commissions, and multistate cooperative purchasing alliances administering contracts on behalf of participating public agencies. The work involves supply of FDA-compliant products meeting specific manufacturing standards, compliance with current Good Manufacturing Practices (cGMP) and the Drug Supply Chain Security Act (DSCSA), maintenance of authorized wholesaler relationships, and fulfillment through quarterly or standing delivery arrangements to public health facilities.

Recent activity concentrates in Florida and the upper Midwest. Seminole County, Florida posted IFB 60459723LAS on June 30, 2026, seeking annual supply of 1,900 units of naloxone and 800 safe drug deactivation systems with quarterly deliveries to the Seminole County Community Health Building (response deadline July 26, 2023). The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued RFP S1070000015802 on January 20, 2026, to establish multiple contracts for generic pharmaceuticals and OTC products distributed across Minnesota, Oregon, and participating state and local facilities, with proposals due March 26, 2026 and awards effective July 1, 2026. The Texas Health and Human Services Commission issued RFI HHS0017013 on April 3, 2026, to gather vendor capabilities regarding direct-to-manufacturer prescription programs. Vendors responding to these solicitations must demonstrate EDI capability, maintain specified insurance coverage, comply with E-Verify requirements, and provide detailed product information including National Drug Codes and manufacturing certifications.